| GTO ID | GTC3018 |
| Trial ID |
NCT05355402
|
| Disease |
Severe Hypertriglyceridemia
|
| Altered gene | APOC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Olezarsen|ISIS 678354|IONIS-APOCIII-LRx|AKCEA-APOCIII-LRx |
| Co-treatment | Clopidogrel |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia |
| Year | 2021 |
| Country | Australia|Bulgaria|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|New Zealand|Norway|Poland|Portugal|Slovakia|South Africa|Spain|Sweden|Turkey|United Kingdom|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 678354-CS8 |